
Biotech IPO Window Reopens, But Big Pharma Acquisitions Remain Strong
The biotech IPO market is showing signs of recovery, but top dealmakers at JPMorgan suggest strong companies may still opt for acquisition by Big Pharma. Investors are more selective, leading many biotechs to pursue dual-track strategies. This trend reflects a broader healthcare dealmaking rebound driven by Big Pharma's need to replenish pipelines.












